Drugs / APL-3007
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07215390 | Jun 2025 → Jun 2027 expected | retinal degeneration | Apellis Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-3007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215390 ↗ |
| Action | Inhibit | “Complement C3 inhibitor” NCT07215390 ↗ |
| Route | Subcutaneous | “APL-3007 SC + pegcetacoplan (APL-2)” NCT07215390 ↗ |